Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Clovis Oncology, execs to pay $20 million to settle SEC charges

Written by: | no-reply@reuters.com | Dated: Tuesday, September 18th, 2018

 

WASHINGTON (Reuters) – U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

The Securities and Exchange Commission said they agreed to the settlement without admitting or denying the allegations, and that the settlements are subject to court approval.

According to the SEC, Clovis continually told investors that its drug, Roci, caused targeted tumors to shrink in 60 percent of patients, when data showed it had actually caused tumor shrinkage in 42 percent of patients.

Once Clovis disclosed the true efficacy rate at the end of 2015, its stock price dropped about 70 percent, the SEC added.

 

Reporting by Lisa Lambert; Editing by Bill Berkrot

 

Reuters source:

https://www.reuters.com/article/us-sec-clovis-oncology/clovis-oncology-execs-to-pay-20-million-to-settle-sec-charges-idUSKCN1LY2PD

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom